Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Sanofi India Limited
SANOFISanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH. Address: Sanofi House, Mumbai, India, 400072
Analytics
Zielpreis von Wall Street
785 823.24 INRKGV
29.4894Dividendenrendite
2.47 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen SANOFI
Dividenden-Analyse SANOFI
Dividendenwachstum über 5 Jahre
430 %Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
132 %Verlauf der Dividende SANOFI
Bewertung der Aktie SANOFI
Finanzen SANOFI
Ergebnisse | 2019 | Dynamik |